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Tämän syventävän työn tarkoituksena oli vertailla kahden eri massaspektrometrimenetelmän, 
SWATH-MS:n ja iTRAQ:n, eroja silmäsolujen proteomiikan tutkimuksissa. Tutkimustyö oli osa 
laajempaa kokonaisuutta, jossa tutkittiin glaukoomalääkkeiden vaikutusta silmän pinnan soluihin. 
Analysoitavina solumalleina käytettiin kahta silmän pinnan solulinjaa, HCE ja NHC. HCE-solulinja 
on kehitetty ihmisen sarveiskalvon epiteelisoluista, ja NHC-solulinja ihmisen sidekalvon soluista. 
Solut altistettiin kahdella eri glaukoomalääkkeellä, tafluprostilla ja latanoprostilla, sekä lääkkeiden 
säilöntäaineella bentsalkoniumkloridilla. Kontrollinäytteinä käytettiin altistamattomia soluja. 
Altistusten jälkeen kummankin solulinjan näytteet analysoitiin kahdella eri 
massaspektrometrimenetelmällä, SWATH-MS ja iTRAQ. 
Menetelmien välillä vertailtiin niiden tunnistamien proteiinien kokonaismäärää ja tunnistamisen 
toistettavuutta, pitoisuusmääritysten luotettavuutta ja tulosten yhteneväisyyttä keskenään. SWATH-
MS:lla proteiineja tunnistettiin huomattavasti enemmän ja toistettavammin kuin iTRAQ:lla. iTRAQ 
vaikutti tulosten perusteella tuottavan luotettavampia pitoisuusmäärityksiä kuin SWATH-MS, mutta 
tulokset analysoitiin pienemmästä määrästä proteiineja. Pitoisuusmääritysten osalta tulokset olivat 
jokseenkin yhteneviä, mutta tuloksissa ei löytynyt lineaarista suhdetta menetelmien välillä.  
 
Tämän opinnäytteen alkuperäisyys on tarkastettu Turnitin OriginalityCheck-ohjelmalla Tampereen 
yliopiston laatujärjestelmän mukaisesti.  
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1 INTRODUCTION 
 
 
1.1 Glaucoma 
 
Glaucoma is a chronic neuropathy of the optic nerve which results in structural changes in optic 
disc and retinal nerve fiber layer, and causes progressive visual field loss (1-3). There are around 50 
different subtypes of glaucoma (1). Primary open-angle glaucoma (POAG) and exfoliation 
glaucoma are the most common subtypes of glaucoma in Nordic countries (4). Other glaucoma 
subtypes contain primary angle-closure glaucoma (PACG), and secondary glaucomas e.g. 
inflammatory glaucoma, pseudoexfoliative glaucoma, pigmentary glaucoma, neovascular 
glaucoma, and traumatic glaucoma (1). The main risk factors for glaucoma are age, elevated 
intraocular pressure, ethnic background, myopia, and positive family history (3). 
The diagnosis of glaucoma is based on ophthalmoscopy, tonometry, and perimetry (3). Usually 
structural changes in POAG progress slowly over the years and patients remain asymptomatic in the 
early stages of disease, while PACG patients may have sudden onset of dramatic symptoms. 
Especially PACG should be diagnosed and treated properly in the early stages of disease because 
the structural changes may progress in a short period of time. (1-3) The symptoms of POAG 
emerging usually in the later stages of disease contain progressively worsening vision (usually 
unilateral) and difficulty with night vision (1). If left undiagnosed and untreated, glaucoma results 
in irreversible visual disability and eventually in blindness (1-3,5). Glaucoma is, in fact, the second 
leading cause of blindness worldwide after cataract (6). 
In order to estimate the global prevalence of glaucoma (POAG and PACG) at present and in the 
future, Tham et al. (2014) examined data from 50 articles in their meta-analysis. In 2013, 64,3 
million people aged 40-80 years were estimated to be affected by glaucoma. The global prevalence, 
thus, was estimated to be 3.54 % among the age-group mentioned above. The prevalence of POAG 
was 3.05 % while the prevalence of PACG was only 0.50 %. The prevalence of glaucoma among 
people aged 40-80 years was predicted to increase by 18.3 % in 2020 and by 74 % in 2040, mainly 
due to aging of the population. Thus, in 2040 112 million people are predicted to be affected by 
glaucoma. (7) 
The objective of the treatment is to prevent visual disability by reducing the risk of development 
and progression of the structural and functional changes. For the present, lowering the IOP 
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(intraocular pressure) is the only treatment form for POAG. (2) 30-50 % reduce from baseline in 
intraocular pressure usually stops the progression of glaucoma changes (3). The treatment 
modalities involve medical therapies, laser therapies, and surgical managements, of which the 
medical therapies are usually the first line treatment (3,8). Five different groups of topical 
medications are currently in use: prostaglandin analogues, beta-adrenergic antagonists, alpha-
adrenergic agonists, cholinergic agonists, and carbonic anhydrase inhibitors. In addition, various 
new drugs are in development for the treatment of POAG including rho kinase inhibitors, adenosine 
receptor agonists, and modified prostaglandin analogs. (9) 
 
1.2 Prostaglandin analogues in treatment of glaucoma 
 
Topical prostaglandin analogues or beta-adrenergic antagonists are usually the first-line treatment 
for POAG (8). However, in various studies prostaglandin analogues have showed to be more 
effective in lowering IOP than beta-adrenergic antagonists (10-15). In addition, prostaglandin 
analogues lack relevant systemic side effects and are administered only once a daily, thus, 
prostaglandin analogues are recommended as first-line therapy for glaucoma treatment by European 
glaucoma society (16,17). 
Latanoprost, tafluprost, travoprost, and bimatoprost are currently available for glaucoma treatment 
in Finland (18). Prostaglandin analogues reduce IOP by increasing aqueous humor outflow in two 
different ways: by increasing uveoscleral outflow and to a lesser degree by increasing trabecular 
outflow facility (19). The IOP-lowering effectiveness among different prostaglandin analogues is 
nearly equivalent, or at any rate the slight differences are not clinically relevant (2,15,20-23). The 
common adverse effects of prostaglandin analogues encompass iris pigmentation, hypertrichosis of 
eyelashes, and intraocular inflammation (1). 
Long term use of topical ocular medication has been reported to cause inflammatory changes in 
ocular surface (24). Those changes have suggested to maybe appear as soon as after one year use of 
topical ocular medication (25). Many topical ocular solutions include preservatives, of which 
benzalkonium chloride (BAC) is the most used (26). BAC has suggested to be responsible for the 
allergic, inflammatory, and toxic reactions rather than medicines themselves (24). The adverse 
effects of BAC have been showed in several in vitro, in vivo, and clinical studies (27-34). BAC has 
showed to cause cell death already at a concentration 0,0001%. The lethal effect of BAC appears to 
be dose-dependent: at low concentrations BAC causes cell death via apoptosis, while at high 
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concentrations cells die via necrosis. (26,31) According to few studies, it appears that prostaglandin 
analogues may have a protective effect against the adverse effects of BAC (29,31).  
 
1.3 Mass spectrometry in proteomics 
 
Proteomics refers to the large-scale study of protein properties (35). Mass spectrometry is currently 
a method of choice in proteomics (36). In addition to protein identification, it is able to provide 
information about various other crucial characteristics including protein-protein interactions, post-
translational modifications, and absolute or relative quantification. Quantitative proteomics enables 
comparative analysis of protein expressions between different biological states, for example disease 
and healthy state. (37)  
 
1.3.1 Mass spectrometer 
 
Mass spectrometer is a device that measures mass-to-charge (m/z) ratios and relative abundances of 
ions. There are many different types of mass spectrometers but all of them have in common three 
main building blocks: an ion source, a mass analyzer, and a detector. The ion source ionizes sample 
molecules and creates gas phase ions. A mass analyzer, which function is based on 
electromagnetism, separates ions according to their m/z. The detector converts the energy of 
incoming particles into a current signal. The signal is registered by the electronic devices and 
transferred to the computer in the form of mass spectra. There are several different types of ion 
sources (e.g. gas discharge, thermal ionization, electron ionization, and electrospray ionization), 
mass analyzers (e.g. time-of-flight (TOF), quadrupole ion trap (QIT), and orbitrap), and detectors 
(e.g. electron multipliers, faraday detector, and photoplate detector). (38) 
 
Mass spectrometers are able only to detect molecules with charge. This is because molecules with 
charge are responsive for electromagnetic fields which are used in mass analysis. (36) Different ion 
types can be formed depending on the molecules and the nature of the ionization process (39). 
Peptides are commonly positive in charge because of the sample preparation using most commonly 
trypsin which creates peptides usually containing at least two positive charges, one at the N-
terminus and another at the C-terminal lysine or arginine (40). In addition, ions can be produced 
also by attracting one or more electrons or even a charge carrying atom or group. However, 
negative and positive ions can’t be detected simultaneously due to polarity of the voltage applied to 
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the detector which is opposite to the ions attracting to the detector. (39) In this study we have only 
used positive charge in peptide analysis. 
 
 
Figure 1. AB Sciex NanoLC 425 coupled to MSTOF mass spectrometer which was used in this 
study. 
 
1.3.2 Separation methods 
 
Samples with high dynamic range (e.g. biological fluids) cause extra challenge for a complete and 
reproducible analysis of protein content. Very abundant proteins may give rise to suppression effect 
that can complicate or preclude the detection of low abundant proteins. Hence, fractionation of 
proteins prior to mass spectrometry analysis is required in order to detect all proteins across the 
dynamic range of a sample. (41) Consequently, in order to increase sensitivity, dynamic range, and 
selectivity, several different separation methods (online or offline) have been applied in conjunction 
with the main building blocks of mass spectrometer. Chromatography and electric-field driven 
separations are such methods. (38)  
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Separation of sample molecules by chromatography is based on the different physiochemical 
properties between the molecules. A chromatographic system consists of a mobile phase and a 
stationary phase. A sample is dissolved in the mobile phase which then carries the sample through 
the stationary phase. The molecules of the sample have different affinities for the stationary phase 
and therefore travel through the stationary phase at different speeds (i.e. have different retention 
times). The two main types of chromatography are liquid chromatography in which the mobile 
phase is liquid, and gas chromatography in which mobile phase is gaseous. (38) In this study we 
used liquid chromatography (AB Sciex NanoLC 425) coupled to MSTOF mass spectrometer 
(Figure 1). 
 
1.4 SWATH-MS 
 
SWATH-MS (sequential windowed acquisition of all theoretical fragment ion mass spectra) is a 
label-free mass spectrometric technique for qualitative and quantitative protein determination. The 
method was first published in 2012 by Gillet et al. SWATH-MS combines data-independent 
acquisition method (DIA) with a targeted data extraction strategy and provides reproducible and 
accurate quantification with high identification rate. (42) Figure 2 illustrates the workflow of 
SWATH-MS. 
 
In SWATH-MS, the mass spectrometer repeatedly cycles through usually 25Da wide (can be 
adjusted) isolation windows, “swaths”, across the mass range in interest (generally 400-1200m/z) 
(42). With DIA mode, all precursor ions that fall into the isolation window are fragmented 
simultaneously and spectra of all fragment ions is acquired (43). During the entire chromatographic 
separation, the same precursor isolation window is fragmented over and over again. Hence, merely 
by one single injection, this acquisition method is able to generate a complex fragment ion map that 
is continuous in both fragment ion intensity and retention time dimensions. (42,43) 
 
After data acquisition, the peptides can be identified and quantified by targeted data extraction 
strategy. Identification and quantification are both performed from MS2 spectra. SWATH-MS can 
be applied only on a fast, high resolution MS instrument in order to achieve highly specific 
fragment ion data of all the precursor ions. (42) Currently SWATH-MS is available for various LC-
MS/MS devices. 
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1.4.1 Spectral libraries 
 
The data analysis in SWATH-MS quantification requires spectral libraries that have been generated 
beforehand (42). Fragment ion maps generated by data acquisition are compared to spectral libraries 
in order to find matches (44). Spectral libraries contain information about peptide characteristics 
(e.g. fragment ion signals, their relative intensities and chromatographic concurrence) which is 
utilized in peptide identification. The peak areas and intensities of identified peptides are used to 
assess the relative abundances. (42) 
 
Shotgun proteomics is a mass spectrometric method that allows identification of at least thousands 
of proteins from a sample, and thus is usually utilized in making of spectral library, which is also 
used in iTRAQ method. In shotgun proteomics, mass spectrometer uses data-dependent acquisition 
mode (DDA), in which a number of the most abundant peptides in given chromatographic elution 
time are selected to fragmentation and recorded in MS scan. (44) Building a library starts with the 
selection of representative samples that are then analyzed with DDA method preferably with the 
same instrument than subsequent SWATH-MS analyses (45).  
 
Alternatively, the fragment ion spectra can be built from synthetic peptides or recombinant proteins 
or they can be computationally predicted (45-47). After acquisition, the DDA data will be processed 
and searched against protein sequence database. Finally, consensus spectral library will be built 
from confidently assigned spectra, and SWATH-MS spectral library will be generated from it by 
selecting the most intense fragment ions for each precursor. (45) Instead of building a spectral 
library, nowadays some proteome-wide spectral libraries are completed and publicly available for 
SWATH-MS analysis. Recently a library containing over 10,000 human proteins were developed 
and optimized for SWATH-MS. (43,45,48-50) 
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Figure 2. The workflow of the SWATH-MS. First, proteins in a sample are extracted and 
enzymatically digested. The sample is then analyzed by LC-MS/MS mass spectrometer. The 
outcome is a complex fragment ion map which is continuous in three dimensions: time, m/z, and 
peak intensity. In order to identify and quantify proteins, the fragment ion map is matched with 
spectral library that has been generated beforehand e.g. using shotgun proteomics.  
 
1.4.2 The pros and cons of the SWATH-MS 
 
Selected reaction monitoring (SRM) is considered the gold standard of proteomic quantification 
methods (42). However, SRM requires targeted proteins to be determined prior to data acquisition 
and is able to quantify approximately 50-100 proteins in a single run without compromising 
identification and quantification accuracy (51). SWATH-MS provides greatly higher throughput 
than SRM with possibility to identify and quantify at least thousands of proteins (Table 1). First of 
all, high throughput is due to DIA method which acquires data independently on a priori protein 
determination. Second, permanent digital records of SWATH-MS data allow reanalysis with more 
complete spectral libraries and thus enables higher throughput. (42,43)  
 
Moreover, it has been showed that SWATH-MS is sensitive enough to identify and quantify 
peptides down to the hundred amol range which is a little poorer than sensitivity of SRM (42). 
However, the performance of SWATH-MS depends vitally on coverage and quality of spectral 
Sample Sample
Protein extraction and 
tryptic digestion
Analysis (LC-MS/MS 
instrument) MS1
MS2
LC
Shotgun MS
Spectral
library
SWATH-MS data acquisition Spectral library
Peptide-spectrum
matchingà
identification and 
quantification
m/z
In
te
ns
ity
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libraries. Thus, the ideal library would contain at least all peptides in interest or even whole 
proteome. (45) 
 
Other performance characteristics such as dynamic range, reproducibility, and accuracy of 
quantification has proved to be comparable with SRM (42,44,51,52). SWATH-MS is able to 
quantify peptides reproducibly at least over a dynamic range of 4 orders of magnitude (42,52).  
The reproducibility of quantification is usually estimated via coefficient of variation (CV). 
Coefficient of variation denotes the ratio of standard deviation to mean. In SWATH-MS 
experiments, the CVs have been relatively small referring to high reproducibility of quantification. 
The quantification has also discovered to produce accurate measurements. (Table 1) In two studies, 
a small ratio compression effect has been reported with SWATH-MS (44,53). Samples with higher 
protein loads and larger fold changes increased the underestimation effect (44). However, in general 
the reproducibility and accuracy have thought to remain high from simple samples to more complex 
samples, even in whole cell proteome complexity level (42,44,52).  
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Table 1. Studies that evaluate the performance characteristics of SWATH-MS.
Study Sample LC-MS/MS	set	up Number	of	identifications Reproducibility Accuracy	of	quantification
Huang et 
al. (2015) 
(44)
Mouse 
fibrosarcoma 
cells
TripleTOF™ 5600+ + 
Eksigent 425 nano 2D 
HPLC
In total 3600 proteins across four samples (and 
three technical replicates of each) which 
contained different peptide mixture loads 
(0,25µg, 0,5µg, 1µg, 2µg). More proteins were 
identified when more peptide mixture was 
loaded: 410 proteins more were identified when 
peptide mixture load increased from 0,25µg to 
2µg.
CV%s were determined on transition 
ion, peptide, and protein levels. 
Quantification variance was smaller on 
samples with higher protein amounts. 
For the sample containing 2µg peptide 
mixture: CV% < 10% for 84% of the 
proteins and CV% < 20% for 91% of 
the proteins. CV < 20% for 88%, 83%, 
and 78% of the proteins (1µg, 0,5µg, 
and 0,25µg respectively).
Samples with different protein loads 
and theoretical protein ratios (1:2, 1:4 
and 1:8) were quantified: all measured 
ratios were smaller than theoretical 
ratios. Samples with higher protein 
loads and larger fold changes were 
underestimated the most. However, 
measurements with theoretical 1:1 ratio 
showed very high quantification 
precision and accuracy.
Bourassa 
et al. 
(2015) 
(53)
Duodenal tissue 
biopsies
TripleTOF 5600, 
Agilent 1200 HPLC
A total of 2,290 proteins. Bovine serum albumin was spiked into 
samples at 1:50 ratio. Ratio values 
from experiment were 29,5 +/- 5 thus 
indicating a small compression effect.
Selevsek 
et al. 
(2015) 
(52)
Saccharomyces 
cerevisiae -yeast
TripleTOF™ 5600 + 
NanoLC-2Dplus 
HPLC system 
(Eksigent)
2578 proteins were detected confidently in 
single run. In further examinasions of 
reproducibility of identification, 2880+-7 
proteins were identified in single run, and 80% 
of those were detected in all four runs and more 
than 90% were detected in three of four runs.
CV% of the integrated transition peak 
areas across four runs were determined 
(included only peptides detected in all 
runs): CV% ≤ 10% for 76% of the 
assays and CV% ≤ 40% for 96% of the 
assays. CVs were comparable between 
low and high signal intensities.
Mixtures containing two differentially 
labeled tryptic digests in 1:1 ratio and 
1:10 ratio were quantified: fold 
changes were 0,92±0,14 for 1:1 ratio 
and 10,47±4 for 1:10 ratio.
Zhang et 
al. (2014) 
(84)
Two non-small-
cell lung cancer 
cell lines
Triple TOF 5600, 
NanoLC-2D Ultra
A total of 824 proteins were identified. 562 of 
those were quantified repeatedly in three 
technical replicates.
Gillet et 
al. (2012) 
(42)
Saccharomyces 
cerevisiae -yeast
TripleTOF™ 5600 
and Eksigent 1D+ 
Nano LC system 
(reproducibility 
experiment) or 
Eksigent Nano-LC-
2D+ + nanoFlex 
cHiPLC system 
(quantification 
accuracy experiment)
CV% was determined from 23 peptides 
which were spiked at constant 
consentrations into samples containing 
yeast trypsin digest as proteomic 
background: 13.7%.
The experiment was performed as in 
(Picotti, P. et al. 2009). Samples were 
tryptic digests of a mixture of 1) lysate 
of yeast cells that sampled throughout 
the metabolic shift from fermentation 
and respiration and 2) 15N-labeled 
yeast lysate background (internal 
standard for the fold change 
calculations). Quantification accuracy 
achieved the same level than accuracy 
of SRM.
 
 
1.5 iTRAQ 
 
iTRAQ (isobaric tags for relative or absolute quantitation) is a mass spectrometric technique used 
widely in quantitative proteomics (54). It was developed by Applied Biosystems (nowadays Sciex) 
in early 2000. iTRAQ utilizes isobaric tagging reagents enabling simultaneous identification and 
quantification of proteins using LC-MS/MS (37,55). Figure 4 illustrates the workflow of the 
iTRAQ. 
 
The iTRAQ reagents were originally designed for simultaneous analysis up to 4 different biological 
samples but are nowadays available also as an 8-plex kit and 12-plex kit (55,56). The reagents 
consist of a peptide-reactive group (NHS ester) and an isobaric tag, that consist of a reporter group 
(N-methylpiperazine) and a mass balance group (carbonyl) (Figure 3). The isobaric tags differ in 
isotopic compositions of oxygen, nitrogen and carbon. (55) The reporter group masses for 4-plex 
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range from m/z 114.1 to m/z 117.1, and for 8-plex masses are 113.1, 118.1, 119.1 and 121.1 (54). 
The balance group also ranges in mass, thus keeping the combined mass of tag identical across 
different tags (55). Reporter ion masses have been designed carefully in order to avoid interference 
by ordinary peptide fragments, thus m/z 112 and 120 were excluded as reporter ions for 8-plex kit 
because arginine and phenylalanine have the same mass (56,57). The peptide-reactive group 
specifically reacts with primary amines of peptides and forms an amide linkage to N-terminal of 
peptide or Ɛ-amino group of the lysine side-chain (55). Hence, almost all peptides that exist in a 
sample are labeled and can be identified and quantified (37). 
 
 
Figure 3. Based on a figure by Ross et al. (2004). iTRAQ reagents consist of a peptide-reactive 
group and an isobaric tag which includes a reporter group and a mass balance group. The peptide-
reactive group reacts with primary amines of peptides while reporter groups are used to assess 
quantities of peptides. The function of the balance group is to keep the mass constant across 
different tags. The tags differ in isotopic compositions of oxygen, nitrogen, and carbon. (55)  
 
After labeling step, samples are pooled and analyzed by LC-MS/MS (55). Every identical peptide 
from each sample appears as a single peak in the MS1 spectrum because of the isobaric nature of 
the reagents. During further fragmentation in MS/MS, there is a neutral loss of balance group and 
reporter group ions are released yielding ions at different m/z. The intensities of reporter ion peaks 
are directly proportional to the relative abundances of peptides before labeling. In addition to 
reporter ion peaks, series of y- and b-ions are produced, and can be used for identification or 
sequence confirmation. (37) 
 
O
N
O
N
O
Balance group
Reporter group Peptide-reactive group
Isobaric tag
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Figure 4. The workflow of the iTRAQ. Proteins from samples are first extracted and enzymatically 
digested. Following digestion, peptides are labeled with iTRAQ labeling kit and pooled. Up to 
twelve samples can be labeled and analyzed simultaneously. Pooled samples are analyzed using 
LC-MS/MS instrument. Identical peptides from all samples appear as a single peak in MS1 
spectrum, from which identifying is performed. After further fragmentation during MS2, iTRAQ 
reporter group ions are released. Reporter group ions from different samples appear as different 
peaks in MS2 spectrum, from which quantifying can be performed. 
 
iTRAQ labeled samples can be analyzed by variety of MS/MS platforms: Q-TOFs, TOF-TOFs, Ion 
traps, and Orbitraps (55,58-60). At the beginning, ion traps suffered from the poor capability to 
detect the low m/z reporter ions: fragment ions with m/z values less than 25-30% of the precursor 
ion m/z values were not detected in MS2 spectrum (61). However, several methods, including 
pulsed Q dissociation (PQD), higher-energy C-trap dissociation (HCD), and combined collision-
induced dissociation (CID) and HCD, have been developed to overcome this limitation (58,62,63). 
Recently, comparison of LTQ Orbitrap Velos, 4800 MALDI-TOF/TOF, and 6530 Q-TOF showed 
that the identification rate was highest with Orbitrap which identified approximately four times 
more proteins than the other instruments did. Further, Orbitrap and MALDI proved to be the most 
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trustworthy with respect to quantification (bias and variance were evaluated), whereas QTOF 
showed poorer results. (64)  
 
1.5.1 The pros and cons of the iTRAQ 
 
At its best, iTRAQ is able to reliably identify up to thousands of proteins. However, protein 
identification rate varies largely between different experimental settings and LC-MS/MS 
instrumentation. (Table 2)  
 
Concerns about accuracy of quantification have been arisen. Accuracy refers to how much the 
observed values differ from the true values, and is affected by systematic bias. Underestimation of 
fold changes of protein expressions has proved to be the main challenge with iTRAQ, and has been 
reported by several studies. (54,59,64-66) It has been named ratio compression as it arises from 
iTRAQ’s tendency to compress ratios towards 1, thus reporting the observed fold changes smaller 
than the true fold changes are (37). Ratio compression has seen to become more pronounced with 
larger fold changes (65,66). However, the trends of up- or down-expression should be correct (54). 
Ratio compression has been observed across different mass spectrometric instrumentations and 
experiments, thus showing to be independent on the LC-MS/MS instrumentation (Table 2). The 
fold changes smaller than twofold have been concluded to be difficult to detect (66).  
 
Cross-label isotopic impurity is one cause leading to ratio compression. Impurities arise mainly 
during manufacture and are expected. Hence, the effect of isotopic impurities can be corrected 
during analysis. Manufacturer commonly provides correction information with regard to the 4-plex. 
The correction of the effect of isotopic impurities for 8-plex is more difficult. The label-dependent 
percentage contamination must be determined by MS/MS and once values are known, correction 
algorithms can be applied to reduce underestimation. (54) 
 
More serious factor affecting ratio compression is the background contamination that arises from 
interfering ions (59,65). When precursor ion is selected for fragmentation during MS/MS, also one 
or more, co-eluting precursor ions with similar m/z, are selected as well. Therefore, the precursor 
ion in demand and spare precursor ions are sequenced and quantified at the same time. This raises 
reporter ion intensities and results in compression of the ratio. (54) The result is mixed MS/MS 
spectra which impairs accuracy of fold change determinations (54,59). In addition, because mixed 
MS/MS spectra contain unidentifiable fragment ions, they also impair identification rate in large-
scale data sets (67). This co-isolation is proportional to sample complexity (59). 
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Several studies have tried to find a solution for background contamination issues. Narrowing the 
MS/MS isolation width is one approach to reduce the effect of background contamination. In 
theory, with narrower isolation window fewer interfering ions are co-selected and co-fragmented. 
(59,65) Bantscheff et al. (2008) performed four LC-MS/MS runs with different precursor ion 
isolation widths. The observed fold changes were significantly lower than the expected ratio in all 
four cases. At narrow isolation widths the ratio were closest to the expected value, thus showing 
that the presence of increasing amounts of nearly isobaric peptides significantly contribute to the 
total reporter ion intensities. (59) However, Karp et al. (2010) investigated three different isolation 
window widths (2-fold increase in the contamination) and observed no statistically significant 
difference between settings suggesting that other factors have more effect on background 
contamination than isolation window width (65). In addition, narrowing the isolation window 
decreases the signal intensity and results in poorer limit of quantification (59). 
 
Ow et al. (2011) focused on minimizing sample complexity by effective fractionation prior to 
MS/MS. They observed that instead of using a typical low-/medium-resolution fractionation 
technique, using a high-resolution fractionation technique (HILIC) reduces the ratio compression. 
Based on their results the accuracy can be improved approximately 20% with high-resolution 
fractionation technique. (68)  
 
Few studies have tried to eliminate issues through different modifications on the data acquisition 
stage (69-71). Wenger et al. (2011) developed a method called QuantMode in which they applied 
gas-phase purification method. Proton-transfer ion-ion reactions reduce ion charge state thus 
changing m/z values of ions. This results in purified precursor ion population for further 
fragmentation and provides improved accuracy and precision. (70) This method was originally 
designed for high-resolution QLT-Orbitrap hybrid systems, but recently, Vincent et al. (2013) 
extended this method to encompass low resolution devices too. (70,71)  
 
Ting et al. (2011) applied triple mass spectrometry (MS3) in order to enhance the ion selection 
specificity. The most intense MS2 fragment ion was selected for M3 stage and used to provide 
quantitative data. This method improved both accuracy and precision by almost completely 
eliminating the adverse effect of interfering ions. Unfortunately, also with this method 12% 
decrease in quantified proteins was reported, and it can be applied only for ion trap instruments. 
(69)  
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Karp et al. (2010) proposed a method to address accuracy problem in data analysis stage. They 
observed a linear relationship between the expected and the observed ratios, and proposed that 
readings of known proteins that span through the range of expected ratios can be used to calculate a 
single correction factor. For complex samples in which linear relationship is thought to be disturbed 
they proposed development of a kit that consists of a mixture of proteins at known ratios. This 
mixture would be added to samples before iTRAQ labeling, and after acquisition proteins at known 
ratios would be used to calculate the correction factor. (65)  
 
In addition to concerns of accuracy of quantification, also concerns about precision has been arisen. 
Precision refers to how reproducible the repeated measurements are, and is affected by random 
errors. (65,66) On one hand, it depends on the quality of individual mass spectrum, and on the other 
hand, it depends on the number of available spectra for quantification (59). The precision issues are 
independent on LC-MS/MS instrumentation, labeling kit (4-plex or 8-plex), and analytical packages 
(65). Precision has been found to be the function of mean abundance: variance is higher for low 
intensity signals than for high intensity signals (58,59,65,66,72,73). This is significant problem 
because low intensity signals dominate the data sets, and in biological studies low intensity peptides 
may be among the most interesting peptides (65).  
 
Several statistical analysis methods have been proposed to minimize variation and thus address 
precision issue. Such methods are for example outlier removal, weighted means, inclusion filters, 
and logarithmic transformation. (65,74-76) However, according to Karp et al. (2010), these methods 
discovered not to be able to address the precision issue while maintaining sensitivity. 
Karp et al. (2010) applied a variance stabilizing transformation to address the precision issue. This 
method stabilizes variance across all intensity ranges and simplifies the downstream analysis. In 
addition, it allows using low intensity readings which is necessary with biological samples. 
However, there is a drawback: the ratios of small peak areas are compressed towards one thus 
making underestimation issue more pronounced. (65)  
 
Recently, Mahoney et al. (2011) recommended weighted least squares (WLS) differential 
expression model over the VSN. In WLS a weight is given to each abundance value: the peptides 
that have been measured with less variance are given more weight and the peptides that have been 
measured with greater variance are given less weight. (66)  
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Table 2. Studies that evaluate the performance characteristics of iTRAQ.
Study Sample LC-MS/MS	set	up Number	of	identifications Reproducibility Accuracy	of	quantification
Bourassa 
et al. 
(2015) 
(53)
Duodenal tissue 
biopsies
TripleTOF 5600, 
Agilent 1200 HPLC
A total of 3,886 proteins in at least one 
replicate.
The compression effect was seen in 
linear regression model, volcano plot 
and density plot.
Zhang et 
al. (2014) 
(84)
Two non-small-
cell lung cancer 
cell lines
Triple TOF 5600, 
NanoLC-2D Ultra
966 and 995 proteins were identified in two 
technical replicates. 636 of those were 
quantified repeatedly in two technical replicates.
Hultin- 
Rosenberg 
et al. 
(2013) 
(64)
Lung cancer cell 
line A549
1200 nano-LC + LTQ 
Orbitrap Velos or 
Ultimate 3000 LC + 
4800 MALDI-
TOF/TOF or 1200 
nano-LC + 6350 
QTOF
Orbitrap 2,453 proteins, MALDI 620 proteins, 
QTOF 238 proteins.
The relative standard deviation (RSD) 
per peptide was calculated across the 
eight iTRAQ channels. RSD was 
considerably higher for the peptides 
with low intensity.
The fold change for all peptides was 
calculated and related to minimum 
peptide signal intensity. The fold 
change compression toward one was 
seen idependent on intensity level. The 
fold changes were approximately 5% 
lower than the expected fold change.
Mahoney 
et al. 
(2011) 
(66)
Saccharomyces 
cerevisiae -yeast 
as background, 
16 non-yeast 
spike-in proteins
LTQ Orbitrap or 
MALDI 4800 
TOF/TOF
In total 1449 proteins from 3 studies (ten 
samples) were identified. 99% (1436) of the 
proteins was identified in study 1 (four samples, 
Orbitrap), 35% (512) of the proteins was 
identified in study 2 (four samples, MALDI), 
and 22% (312) of the proteins was identified in 
study 3 (two samples, MALDI). 19% (273) of 
the proteins was identified in all three studies.
Median CV% were calculated for each 
study: for study 1, 2, and 3  CV%s were 
25%, 12%, and 17% respectively. In all 
three studies CV% was higher for 
peptides with lower abundance.
The expected fold changes of 16 non-
yeast proteins were compared to the 
observed fold changes: the observed 
fold changes were underestimated. The 
bias increased as the expected fold 
changes increased but was independent 
on molecular weight and the amount of 
protein spiked into the mixture.
Karp et al. 
(2010) 
(65)
Erwinia, proteins 
at known ratios 
(BSA, 
Cytochrome c, 
Enolase, 
Phosphorylase 
b), yeast grown 
under 
nutritionally 
limiting 
conditions
QSTAR or LTQ-
OrbitrapXL
Number of identifications were calculated from 
samples that contained yeast grown under 
nutritionally limited conditions. Variance-
stabilizing transformated data yielded 923-1,042 
identified proteins in one sample. Log-
transformed data yielded 923-1,040 identified 
proteins in one sample.
An aliquot of the same sample was 
labelled by each isobaric tag and then 
combined before data acquisition by LC-
MS/MS. Different sample types, 
MS/MS systems and both, 4-plex and 8-
plex tags were used. The variance 
observed to be more pronounced for 
low intensity peptides than for high 
intensity peptides. This effect was 
irrespective of iTRAQ labeling kit, LC-
MS/MS instrumentation, and analytical 
packages.
Four proteins at known ratios (up to 
fourfold) were spiked in unchanging 
amount of background. Systematic ratio 
underestimation was observed, and 
there was a linear relationship between 
the expected and the observed ratios. 
Underestimation became more obvious 
for larger fold changes and was 
independent on LC-MS/MS 
instrumentation.
 
1.5.2 4-plex versus 8-plex 
 
Few studies have compared different labeling kits of iTRAQ (77-79). Pichler et al. (2010) compared 
iTRAQ 4-plex, TMT 6-plex and iTRAQ 8-plex with respect to the numbers of identified peptides 
and proteins in shotgun proteomics experiments. They used an LTQ Orbitrap mass spectrometer, a 
hybrid CID-HCD method, and Proteome Discoverer software for data acquisition and analysis. 
Study was performed with both a mixture of complex biological sample (HeLa cells lysates), and a 
mixture of standard proteins in defined ratios. They observed that in comparison to 4-plex the 
number of unique peptides was more than 70% lower and the number of proteins was more than 
60% lower with iTRAQ 8-plex labeling for both the standard proteins and the complex biological 
sample. They considered that the different peptide identification rates result probably from several 
factors. (77)  
 
In contrast, Pottiez et al. (2012) found divergent results in their study using human plasma as a 
highly complex sample. Data acquisition and analysis was performed by using ABsciex 4800 
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MALDI-TOF/TOF mass spectrometer and ProteinPilot 4.0 software. First, they observed that 
peptide labeling with 8-plex provides better accuracy of quantitation compared to 4-plex without 
compromising on peptide or protein identification. Identification rates for proteins and peptides 
were slightly lower for 8-plex compared to 4-plex but the differences were not significant. Second, 
they observed that when confidence of protein identification decreases, the ratios for individual 
proteins dispersed in both instances. This impact was, however, lesser for 8-plex tags. (78)  
 
Unlike the previous two studies which used peptide-level labeling, Nie et al. (2013) applied protein-
level labeling strategy to study performance between iTRAQ 4-plex, iTRAQ 8-plex, and TMT-6. 
They studied serum glycoproteins by using Orbitrap Elite mass spectrometer and Proteome 
Discoverer software for data acquisition and analysis. In agreement with Pichler et al. (2010), they 
also observed that peptide and protein identification rates were highest with iTRAQ 4-plex when 
compared to TMT 6-plex and iTRAQ 8-plex: 20% fewer proteins were identified and quantified 
using 4-plex kit compared to 8-plex kit. TMT-6 and iTRAQ 8-plex showed to have similar 
performance in contrast with the results of Pichler et al. (2010). (79)  
 
1.6 The aim of this study 
 
For clinical purposes, one main target is to identify proteins as specific biomarkers for diseases. 
Those biomarker proteins vary in abundance between healthy and disease states, and in some cases 
they may exist only in either state. Specific biomarkers will help in understanding underlying 
pathogenic mechanisms of diseases, in discovering early and sensitive diagnostic tools, in 
identifying therapeutic targets, and in predicting of therapeutic outcome. (37,41) 
 
In this study, the aim was to investigate the performance characteristics of two mass spectrometric 
methods for in vitro proteomic studies of conjunctival and corneal cells. This study was part of a 
larger entity in which we studied the effects of glaucoma medication to the conjunctival and corneal 
cells of the eye. Two cell lines, NHC and HCE cells, were used as analyzed samples. The cells were 
exposed to two glaucoma medicines, tafluprost and latanoprost, and in addition, to preservative 
benzalkonium chloride (BAC). Unexposed cells were used as a control samples. After exposures, 
the samples were analyzed by two different mass spectrometric methods, SWATH-MS and iTRAQ. 
My part in this study was to process the SWATH-MS samples after exposures and prior to mass 
spectrometric analysis, and to compare the results from iTRAQ and SWATH-MS analyses. 
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2 METHODS 
 
 
2.1 Cell lines and exposures 
 
In this study we used two immortalized cell lines: human corneal epithelial (HCE) cells and normal 
human conjunctival (IOBA-NHC) cells. HCE cell line has been produced by immortalizing human 
corneal epithelial cells using a recombinant SV40-adenovirus vector (80), whereas IOBA-NHC cell 
line has been produced via spontaneous immortalization of normal human conjunctival cells 
growing in culture medium (81). Both cell lines show morphologic and functional properties of 
normal corneal and conjunctival epithelial cells, being suitable for in vitro experiments (80,81). 
 
Both cell lines were exposed to benzalkonium chloride (BAC), tafluprost (Taflotanâ, Santen Oy), 
and latanoprost (Xalatanâ, Pfizer). BAC is the most commonly used preservative in topical 
ophthalmic medications (82). Taflotan and Xalatan are prostaglandin analogs which are used in 
treatment of open angle glaucoma. Taflotan is unpreserved preparation while Xalatan contains 0,02 
% BAC as a preservative. After 24h drug exposures, cells were collected for proteomic analysis. 
Unexposed cells were used as a control.  
 
2.2 Sample processing 
 
2.2.1 Cell lysis and protein extraction 
SWATH-MS and iTRAQ samples: To lyse the cells, 100 µl Pierceâ RIPA lysis buffer (Thermo 
Fisher Scientific, San Jose, CA, USA) supplemented with 0.1 % HALTä protease inhibitor cocktail 
(Thermo Fisher Scientific, San Jose, CA, USA) was added onto cells / well and samples were 
dissociated using a pestle. The samples were then mixed with a vortex for 2 min, followed by 
incubation first in an ultrasonic bath for 5 min, and then on ice for 25 min. Samples were then 
centrifuged at 14,800 rpm for 15 min at 4 °C, and supernatants were transferred to clean tubes. 
DC Protein Assay kit II (Bio-Rad, Hercules, CA, USA) was used to determine protein 
concentrations. 60 µg of protein was precipitated by adding cold acetone and incubating overnight 
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at -20 °C. The following day, samples were centrifuged at 14,000 rpm at 4 °C for 15 min, the 
acetone was decanted and samples were left to dry. 
 
2.2.2 Protein digestion 
 
SWATH-MS and iTRAQ samples: Samples were resuspended in 50mM ABC (ammonium 
bicarbonate solution, Sigma Aldrich, St. Louis, MO, USA), 2 % SDS (sodium dodecyl sulfate, 
Sigma Aldrich, St. Louis, MO, USA) solution, mixed with a vortex for 2 min, and centrifuged at 
14,000 rpm for 1 min. In order to reduce disulfide bonds, first 50mM TCEP (Tris-(2-carboxyethyl)-
phosphine, Sigma Aldrich, St. Louis, MO, USA) was added, mixed with a vortex for 2 min and 
centrifuged at 14,000 rpm for 1 min. Then, sample tubes were incubated in interval mixing (15 min 
at 1,250 rpm and 1 min stable) at 60 ˚C for 60 min, followed by centrifugation at 14,000 rpm for 1 
min. Protein digestion steps were performed using FASPä Protein Digestion Kit (Expedeon, 
Cabmbridgeshire, UK): 75 % urea solution was added to Spin Filters and samples were transferred 
to them, followed by centrifugation at 14,000 g for 15 min. Urea solution was added again to the 
Spin Filter and centrifuged. Reconstitution of disulfide bonds was prevented by adding 
iodoacetamide and urea solutions to the Spin Filter and incubating in darkness for 20 min. After 
incubation, samples were centrifuged at 14,000 g for 10 min. Next, samples were washed three 
times with urea solution, followed by centrifugation at 14,000 g for 10 min after each wash. Same 
washing steps were then performed with ABC for three times. Trypsin solution (AB Sciex, 
Framingham, MA, USA) was added at 1:25 (trypsin:protein) ratio and samples were incubated in 
interval mixing (15 min at 1,250 rpm and 5 min stable) at 37 ˚C for 16 hours, followed by cooling 
into 4 ˚C and centrifugation at 14,000 rpm for 1 min. After that, samples were washed two times 
with ABC and centrifuged at 14,000 rpm for 10 min after each wash. Finally, NaCl (sodium 
chloride, FASPkit) was added, followed by centrifugation at 14,000 rpm for 15 min and drying in 
vacuum concentrator until there were left approximately 100 µl. 
 
2.2.3 Desalting 
 
SWATH-MS and iTRAQ samples: Samples were dissolved into 0,1 % TFA (trifluoroacetic acid, 
Sigma Aldrich, St. Louis, MO, USA). The sample clean up tips (Pierce C18 tips, Thermo Fisher 
Scientific, San Jose, CA, USA) were flushed with 50 % ACN (acetonitrile, Sigma Aldrich, St. 
Louis, MO, USA) twice and with 0,1 % TFA twice. Sample solutions were flushed in the tips 5-10 
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times. After that, the tips were washed with 2,5 % ACN + 0,1 % TFA solution twice. Samples were 
then transferred into clean tubes with solution containing 80 % ACN + 0,1 % FA (formic acid, 
Sigma Aldrich, St. Louis, MO, USA). Finally, samples were dried in vacuum concentrator. 
 
2.2.4 iTRAQ labeling 
 
iTRAQ reagents were dissolved into ethanol and processed according to manufacturer’s instructions 
(AB Sciex, Framingham, MA, USA). Samples were dissolved into iTRAQ dissolution buffer and 
labeled with the iTRAQ reagents as shown in Figures 5 and 6: HCE-Control 1 & 2 & 3 with 121, 
114 and 121 tags respectively, HCE-BAC 1 & 2 & 3 with 117, 119 and 117 tags respectively, HCE-
Taflotan 1 & 2 & 3 with 115, 117 and 115 tags respectively, HCE-Xalatan 1 & 2 & 3 with 113, 115 
and 113 tags respectively, NHC-Control 1 & 2 & 3 with 118, 116 and 114 tags respectively, NHC-
BAC 1 & 2 & 3 with 115, 113 and 119 tags respectively, NHC-Taflotan 1 & 2 & 3 with 113, 119 
and 117 tags respectively, and NHC-Xalatan 1 & 2 & 3 with 119, 117 and 115 tags respectively. 
The labeled samples were incubated in interval mixing (15 min at 1,200 rpm and 1 min stable) at 
room temperature for two hours, followed by centrifugation at 13,500 rpm for 5 min. Finally, 
samples were pooled together as indicated in Figures 5 and 6 and dried by vacuum concentrator for 
approximately 1,5 hours. 
 
2.2.5 Desalting of iTRAQ samples 
 
Desalting of labelled iTRAQ samples was performed using UltaMicroSpin Columns (Nest Group 
inc., Southbro, MA, USA) according to manufacturer’s instructions: The column filters were 
conditioned by adding ACN into each filter, followed by centrifugation at 800 rpm for 30 s. This 
step was repeated once. After that, 0,1M TEAB (triethylammonium bicarbonate, Sigma Aldrich, St. 
Louis, MO, USA) was added into each filter and centrifuged at 1,000 rpm for 30 s. This step was 
also repeated once. New collection tubes were transferred under the spin columns and sample was 
added into necessary amount of spin columns (up to 30µg or 100µl per column). Samples were 
centrifuged at 1,000 rpm for 30s. Filtrates were transferred back to spin columns and centrifuged at 
1,000 rpm for 30 s. Spin columns were washed twice with 0,1M TEAB after which 80 % ACN + 
0,1 % FA was added, followed by centrifugation at 1,200 rpm for 1 min and repeated once. Sample 
was desalted altogether three times with same column. All the final elution solutions were collected 
into same tube and dried in vacuum concentrator.  
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2.2.6 Sample reconstitution 
 
Finally, both SWATH-MS and iTRAQ samples were dissolved in 0,1 % FA + 2 % ACN. 
 
2.3 Mass spectrometry analysis 
  
iTRAQ analysis was performed as described earlier (83): Digested peptides were analyzed by 
Nano-RPLC-TripleTOF instrumentation using Eksigent 425 NanoLC coupled to high speed 
TripleTOF™ 5600+ mass spectometer (Sciex, Concord, Canada). A microcapillary RP-LC column 
(cHiPLC® ChromXP C18-CL, 3 µm particle size, 120 Å, 75 µm i.d × 15 cm, Eksigent Concord, 
Canada) was used for LC separation of peptides. Samples were first loaded into trap column 
(cHiPLC® ChromXP C18-CL, 3 µm particle size, 120 Å, 75 µm i.d × 5 mm) from autosampler and 
flushed for 10 min at 2 µl/min (2 % ACN, 0.1 % FA). The flush system was then switched to line 
with analytical column. Cell samples were analyzed with 120 min 6 step gradient using eluent A: 
0.1 % FA in 1 % ACN and eluent B: 0.1 % FA in ACN (eluent B from 5 % to 7 % over 2 min, 7 % 
to 24 % over 55 min, 24 % to 40 % over 29 min, 40 % to 60 % over 6 min, 60 % to 90 % over 2 
min and kept at 90 % for 15 min, 90 % to 5 % over 0.1 min and kept at 5 % for 13 min) at 300 
nl/min. 
Key parameters for TripleTOF mass spectrometer in SWATH ID and iTRAQ library analysis were: 
ion spray voltage floating (ISVF) 2300 V, curtain gas (CUR) 30, interface heater temperature (IHT) 
+125°C, ion source gas 1 13, declustering potential (DP) 100 V. Library for SWATH analysis was 
created from the same samples by information dependent-aquisition (IDA) method and relative 
quantitation analysis was done by SWATH method. All methods were run by Analyst TF 1.5 
software (Sciex, Redwood City, USA). For IDA parameters, 0.25 s MS survey scan in the mass 
range 350-1250 mz were followed by 60 MS/MS scans in the mass range of 100-1500 Da (total 
cycle time 3.302 s). Switching criteria were set to ions greater than mass to charge ratio (m/z) 350 
and smaller than 1250 (m/z) with charge state 2-5 and an abundance threshold of more than 120 
counts. Former target ions were excluded for 12 s. IDA rolling collision energy (CE) parameters 
script was used for automatically controlling CE. SWATH quantification analysis parameters were 
the same as for SWATH ID, with the following exceptions: cycle time 3.332 s and MS parameters 
set to 15 Da windows with 1 Da overlap between mass range 350-1250 Da followed by 40 MS/MS 
scans in the mass range of 100-1500 Da. 
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2.4 Protein identification and quantification 
 
SWATH-MS and iTRAQ library: Protein pilot software version 4.0.8085 (Ab Sciex) was used to 
analyse MS/MS data searched against the UniProt/Swiss-Prot protein database for protein 
identification. 
Some important settings in the Paragon search algorithm in protein pilot were configured as 
follows. Sample type: iTRAQ 4plex (peptide labelled), Cys-alkylation: MMTS, Digestion: Trypsin, 
Instrument: TripleTOF 5600+, Search effort: thorough ID. False discovery rate (FDR) analysis was 
performed in the Protein pilot and FDR <1% was set for protein identification. Only peptides with 
99% confirmation were included in identification and quantification. Shared peptides were excluded 
from quantification that was performed using ProteinPilot software with straight average of 
peptides. 
As part of the SWATH analysis method, relative protein quantification library, was created using 
cell samples from this study. Overall library consisted of 13 different samples and 26 data 
dependent analysis (DDA) runs with same LC gradient and instrument settings which were used for 
SWATH analyses. Library was created using Protein Pilot® 4.5 (Sciex, Redwood City, USA) and 
all DDA runs spectra were identified against UniprotKB/SwissProt. Quantification was done by 
Peak Viewer® and Marker viewer® (Sciex, Redwood City, USA). FDR 1% was used in the library 
creation and only distinctive peptides were used in the quantification. Retention time calibration 
was done for all samples using HMR retention time calibration peptides. Five transitions per 
peptide and 1-15 peptides were used for peak area calculations. 
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Figure 5. The workflow of the iTRAQ and SWATH-MS, NHC cell experiments. All three sample sets 
of NHC cells were analyzed from iTRAQ experiments. Due to failed MS analyses, sample set 
number three from SWATH-MS experiments was excluded from statistical analysis. 
 
Figure 6. The workflow of the iTRAQ and SWATH-MS, HCE cell experiments. All three sample sets 
of HCE cells were analyzed from iTRAQ experiments. Due to failed MS analyses, sample set 
number two from SWATH-MS experiments was excluded from statistical analysis. 
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3 RESULTS 
 
 
3.1 Identified proteins 
 
3.1.1 NHC cell experiments 
 
By the SWATH-MS analysis method, 1,917 proteins were identified from each NHC sample and 
technical replicate. Consequently, the average number of proteins in a sample and in both technical 
replicates were equal to 1,917. (Figure 7) By the iTRAQ analysis method, a total of 1,516 different 
proteins were identified from all samples and technical replicates. However, only 290 (19 %) of 
1,516 proteins were present in all samples and technical replicates. (Figure 7) The average number 
of proteins identified in a sample was 984, and the average number of proteins identified in both 
technical replicates was 513. (Figure 7) 
 
781 common proteins for the SWATH-MS and iTRAQ experiments were identified when the 
proteins present in at least one technical replicate or sample were taken into account. Furthermore, 
1,136 proteins were identified only by the SWATH-MS, and 735 proteins were identified only by 
the iTRAQ. (Figure 8A) However, when only the proteins present in all samples and technical 
replicates were taken into account, the number of common proteins was 242. In that case, the 
numbers of proteins identified only by the SWATH-MS or iTRAQ were 1,675 and 48 respectively. 
(Figure 8A) When proteins present in at least one sample versus all samples were taken into 
account, only 29 % and 12 % of all proteins detected in SWATH-MS and iTRAQ were common for 
the two methods. 
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Figure 7. The number of identified proteins by SWATH-MS (black columns) and by iTRAQ (grey 
columns) in NHC samples. The number of identified proteins are shown when proteins present in at 
least one sample or in all samples are taken into account. The average number of proteins in a 
sample and the average number of proteins in both technical replicates of a sample are also shown. 
 
 
Figure 8. Mass spectrometry method comparison results from the NHC cell experiments (A) and 
HCE cell experiments (B). Grey columns represent the number of proteins identified by both the 
SWATH-MS and iTRAQ. Striped columns represent the number of proteins identified only by 
SWATH-MS whereas black columns represent the number of proteins identified only by iTRAQ. 
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3.1.2 HCE cell experiments 
 
1,920 proteins were identified from each sample and technical replicate when using SWATH-MS 
analysis method. Again, the average number of proteins in a sample and in both technical replicates 
were equal to 1,920. (Figure 9) With iTRAQ analysis method, a total number of identified proteins 
in all samples and technical replicates was 1,137. When only the proteins present in all samples and 
technical replicates were taken into account, the number dropped to 206 (18 %) proteins. 
Furthermore, the average numbers of identified proteins in a sample and in both technical replicates 
were 742 and 381 respectively. (Figure 9) 
 
662 overlapping proteins were identified in the SWATH-MS and iTRAQ experiments when the 
proteins present in at least one sample were taken into account. In that case, 1,258 proteins were 
identified only by the SWATH-MS whereas 475 proteins were identified only by the iTRAQ. 
(Figure 8B) However, only 188 common proteins for the SWATH-MS and iTRAQ were identified 
when the proteins present in all samples and technical replicates were taken into account. 
Furthermore, in that case, 1,732 proteins were identified only by the SWATH-MS, and 18 proteins 
were identified only by the iTRAQ. (Figure 8B) Thus, only 18 % (proteins present in at least one 
sample) and 10 % (proteins present in all samples) from all proteins detected in iTRAQ and 
SWATH-MS were common for the two methods. 
 
 
Figure 9. The number of identified proteins by SWATH-MS (black columns) and by iTRAQ (grey 
columns) in HCE samples. The number of identified proteins are shown when proteins present in at 
least one sample or in all samples were taken into account. Furthermore, the average number of 
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proteins in a sample and the average number of proteins in both technical replicates of a sample 
are shown. 
 
3.2 The quantification reproducibility 
 
The relative standard deviation (RSD) was used to assess the quantification reproducibility. With 
regard to the SWATH-MS experiments, 1,917 proteins from NHC data and 1,920 proteins from 
HCE data were detected in all samples and technical replicates. Furthermore, there were eight 
samples in both, NHC and HCE cell experiments, thus, in total 15,336 and 15,360 measured results 
from the samples were taken into account respectively. With regard to the iTRAQ data, 290 and 206 
proteins were detected in all samples and technical replicates in NHC cell and HCE cell 
experiments respectively. There were nine samples in each cell experiment, thus, 2,610 measured 
results from the samples from NHC cell experiments and 1,854 measured results from the samples 
from HCE cell experiments were included. 
 
3.2.1 NHC cell experiments 
 
A total of 39 % (6,038) of measured results had RSD lower than 10 % in the SWATH-MS data, 
whereas a total of 66 % (1,729) of measured results had RSD lower than 10 % in the iTRAQ data. 
(Figure 10) The range between samples was 12-59 % (233-1,122) in the SWATH-MS data and 59-
70 % (170-203) in the iTRAQ data. The numbers of measured results with RSD below 20 % were 
55 % (8,433) and 88 % (2,297) for the SWATH-MS and iTRAQ respectively. (Figure 10) The 
ranges between samples were 26-73 % (492-1,393) and 83-93 % (240-271) for SWATH-MS and 
iTRAQ respectively. Mean RSD in the SWATH-MS data was 31 % and in iTRAQ data 10 %. 
 
3.2.2 HCE cell experiments 
 
With regard to the SWATH-MS data, a total of 54 % (8,294) of measured results had RSD lower 
than 10 %, and with regard to the iTRAQ data, a total of 62 % (1,151) of measured results had RSD 
lower than 10%. (Figure 10) The range between the samples was 30-65 % (571-1,332) in SWATH-
MS data and 53-66 % (109-135) in the iTRAQ data. In the SWATH-MS data, a total of 72 % 
(11,114) measured results had RSD lower than 20 %, whereas in the iTRAQ data the corresponding 
number was 85 % (1,576). (Figure 10) The range between the samples was 57-82 % (1,086-1,576) 
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in the SWATH-MS data and 73-90 % (151-185) in the iTRAQ data. Mean RSD in the SWATH-MS 
data was 19 % whereas in the iTRAQ data it was 11 %. 
 
 
 
Figure 10. The bar graph shows the percentage values of RSDs below 10 % and 20 % across all 
samples. Results from the NHC cell experiments are shown on the left and results from the HCE 
cell experiments are shown on the right. Black columns represent results from the SWATH-MS 
experiments and grey columns represent results from the iTRAQ experiments. 
 
3.3 Expression level bias and correlation of the expression levels between 
SWATH-MS and iTRAQ 
 
Next, we wanted to examine how precisely SWATH-MS and iTRAQ could quantify protein levels, 
and how similar the expression levels were between the SWATH-MS and iTRAQ. First, we 
evaluated the number of under- and over expressed proteins in each sample, and compared the 
results between the analysis methods. Second, we evaluated how much the expression levels 
differed from each other between SWATH-MS and iTRAQ. Third, we evaluated how similar the 
directions of expression level fold changes were between SWATH-MS and iTRAQ. Finally, we 
evaluated was there any linear relationship in expression levels between SWATH-MS and iTRAQ.  
 
Under/over expression analysis and direction of expression level fold change analysis: 242 proteins 
from NHC cell experiments and 188 proteins from HCE cell experiments were detected in all 
samples and technical replicates and identified by both analysis methods. Thus, a total of 1,452 and 
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1,128 expression level results were included in these analyses from NHC and HCE cell experiments 
respectively. 
 
Expression level difference and linear relationship analyses: In the NHC cell experiments, 781 
proteins were detected in at least one sample or technical replicate and identified by both analysis 
methods. In the HCE cell experiments, the corresponding number was 662. We included all these 
proteins in above-mentioned analyses, and thus, a total of 3,312 and 2,754 measured expression 
level results were included from NHC and HCE cell experiments respectively. 
 
3.3.1 The trends of under- and over expressed proteins 
 
NHC cells: With regard to the SWATH-MS data, in a sample on the average 51 % (124) proteins 
were under expressed, and on the average 49 % (119) proteins were over expressed. 
Correspondingly, in the iTRAQ data the average number of under expressed proteins in a sample 
was 41 % (99) and the average number of over expressed proteins in a sample was 59 % (142). As a 
matter of fact, although the percentage values are quite equal between the two analysis methods, 
there was comparatively more variation in the iTRAQ data than in the SWATH-MS data: standard 
deviations were 8 and 96 for SWATH-MS and iTRAQ respectively. Therefore, the percentage 
values of under- and over expressed proteins are shown in Figure 11 separately for every sample. 
As can be seen from bar graph, while the SWATH-MS results are quite similar between samples, 
there is vast difference between the iTRAQ results (Figure 11). 
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Figure 11. The percentage values of under- and over expressed proteins in each sample. Results 
from NHC cell experiments. 
 
HCE cells: In the SWATH-MS data, the average number of under expressed proteins in a sample 
was 54 % (101), and the average number of over expressed proteins in a sample was 46 % (87). In 
the iTRAQ data, the numbers were 67 % (126) and 33 % (63) respectively. Standard deviation for 
SWATH-MS results was 9, whereas for iTRAQ results it was 78. Likewise in the NHC cell data, 
obviously there was also more variation in the iTRAQ data than in the SWATH-MS data. Figure 12 
shows the percentage values of under- and over expressed proteins for each sample. Again, it can be 
seen from bar graph that there are vast differences between samples in iTRAQ while the SWATH-
MS results are quite similar to each other (Figure 12). 
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Figure 12. The percentage values of under and over expressed proteins in each sample. Results 
from HCE cell experiments. 
 
3.3.2 Correlation of the expression levels between SWATH-MS and iTRAQ 
 
SWATH-MS and iTRAQ showed congruent direction of protein expression fold changes in 51 % of 
the results in NHC cell data, and in 53 % of the results in HCE cell data. There was only a slight 
difference in expression levels of proteins between SWATH-MS and iTRAQ. In the NHC cell data, 
95 % of the expression level results differed from each other less than one, and the corresponding 
number in the HCE cell data was 97 %. This outcome was seen regularly across all samples: the 
standard deviation of expression level results which differed less than one between SWATH-MS 
and iTRAQ was 3 % in both NHC and HCE cell data. There was no linear relationship between the 
expression levels of proteins from the iTRAQ and SWATH-MS experiments in either cell line data 
(R2=0,000035-0,05765), i.e. the expression level results didn’t correlate between the analysis 
methods.  
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4 DISCUSSION 
 
 
In this in vitro study, we compared two different mass spectrometric methods; the SWATH-MS and 
iTRAQ. Only two previous studies have compared the specific methods mentioned above (53,84). 
First we evaluated the number of identified proteins by two different methods. Due to nature of 
SWATH-MS analysis, the number of identified proteins depends on the coverage of spectral library 
(42). From a few hundred to few thousand proteins have been identified by SWATH-MS in 
previous studies (44,52,53,84). In our study, we identified 1,920 and 1,917 proteins which were all 
detected in all samples and technical replicates. Thus, SWATH-MS proved to provide reproducible 
identification across all samples. By contrast, we identified 1,516 and 1,137 proteins by iTRAQ. 
However, only less than a fifth of those were detected in all samples and technical replicates. 
Similar to our iTRAQ results, in previous iTRAQ studies, the number of identified proteins ranged 
also from few hundred to few thousand (64-66). In two previous studies comparing SWATH-MS 
and iTRAQ, more proteins have been identified by iTRAQ (53,84). Our results differ from those 
since we identified more proteins by SWATH-MS. The difference was emphasized especially when 
observing proteins present in all samples and technical replicates (Figure 8). 
 
In order to evaluate the quantification reproducibility, we assessed relative standard deviations 
(RSDs, also known as coefficient of variation = CV). Comparison between the methods indicated 
that iTRAQ would have better quantification reproducibility. iTRAQ RSD values were relatively 
more often below 10 % or 20 % when compared to SWATH-MS RSD values. However, the 
number of analyzed results from the SWATH-MS data was considerably higher: 6-fold in NHC cell 
data and 8-fold in HCE cell data. With regard to the SWATH-MS, the results indicated more 
reproducible quantification in the HCE cell experiments than in the NHC cell experiments. By 
contrast, the results from the iTRAQ data were more consistent between the cell lines. With regard 
to iTRAQ, the variance of expression level results has been proved to be higher for low intensity 
peptides. Moreover, the effect has been irrespective of labeling kit, mass spectrometric 
instrumentation, or analytical packages (64-66). With regard to SWATH-MS, variance has been 
proved to be comparable between high and low intensities, however, variance has been smaller on 
samples with higher protein amounts (44,52). In our study, we didn’t evaluate dependence between 
RSD and protein intensities or sample load. 
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There are several ways to estimate the correlation of the protein quantification results between 
SWATH-MS and iTRAQ. To begin with, we evaluated the number of identified proteins by both 
analysis methods: only 10-29 % of all proteins were common for the two methods, depending on 
included proteins (present in at least one or in all samples). Our results were not as good as in 
previous studies, in which 37-51 % of all identified proteins were detected by both methods (53,84). 
Next, the similarities in direction of protein expression fold changes was evaluated between the 
methods. Bourassa et al. (2015) showed that SWATH-MS and iTRAQ agreed on the direction of 
the fold changes 92-98 % depending on used threshold (53). Our results didn’t achieve that level: 
SWATH-MS and iTRAQ agreed on the direction only on 51 % in the NHC cell experiments and 53 
% in the HCE cell experiments. Across all samples in the SWATH-MS data, approximately half of 
the proteins were under expressed and the other half over expressed, while in the iTRAQ data, most 
of the proteins in a sample were either under- or over expressed. (Figure 11 and 12) Hence, the 
foregoing is the main reason for poor correlation of the direction of fold changes between the 
methods.  
 
To further examine the correlation of expression levels results between SWATH-MS and iTRAQ, 
we included all proteins present in at least one sample or technical replicate in next analyses. Only 5 
% of proteins in the NHC cell data and 3 % of proteins in the HCE cell data yielded expression 
levels which differed more than one from each other between the methods. Thus, the expression 
levels of proteins were quite consistent between the two methods. Finally, we evaluated if there was 
linear relationship in expression levels between the methods, which was not found. In theory, 
SWATH-MS and iTRAQ should have yielded similar expression level results for proteins since 
samples were exposed and processed similarly (apart from iTRAQ labeling) prior to mass 
spectrometric analysis. On one hand, the lack of linear relationship may be since the expression 
levels were small enough to fit in the error limits of the methods. On the other hand, those 
maximum 5 % of the proteins which differed more than one from each other between the analysis 
methods might have differed enough to eliminate linearity. 
 
As discussed in introduction, underestimation of protein expression fold changes has proved to be 
the main challenge with the iTRAQ (54). Ratios are compressed towards one, thus, observed fold 
changes are reported smaller than true fold changes are. The effect is more pronounced with the 
larger fold changes. (37,65,66) However, the directions of fold changes have proved to be correct 
(54). In two previous studies, a small underestimation effect has been seen also with SWATH-MS 
(44,53). 1:1 ratios were quantified with high accuracy, and larger fold changes were more 
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underestimated as seen in iTRAQ studies too (44). However, the underestimation effect of iTRAQ 
is more eminent (53). 
 
In conclusion, we compared two proteomic methods in this in vitro study. SWATH-MS proved to 
be superior to iTRAQ especially regarding the identification rate and reproducible quantification. 
Based on the results of this study and previous studies, we would recommend using primarily 
SWATH-MS in corresponding analyses in future. 
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